We are all familiar with the phrase, “Save the Best for Last,” and as we finish up our special GLP-1 Series, we have done exactly that.
This week we have the completion of an interview that our publisher, Steve Freed, did with Dr. David D’Alessio, Associate Professor of Medicine, Division of Endocrinology, University of Cincinnati, about GLP-1 like compounds, beta cells and glucose toxicity.
We also have an upfront and personal interview that Steve had with Dr. Alan Moses, Chief Medical Officer at Novo Nordisk. During this conversation Dr. Moses shared some great info on GLP-1 Analogs, where the future might take us and current studies that Novo has on both Victoza and their new ultra long acting insulin degludec.
Steve, Andrew and I all send our greetings from AADE. Please look for our comprehensive coverage in upcoming issues.